Corrections & Amplifications -- WSJ
09 Juillet 2016 - 9:02AM
Dow Jones News
A Nielsen Holdings PLC executive spoke at a conference about how
proposed Treasury Department tax rules could raise the company's
tax rate. A Business News article Thursday about the rules
incorrectly implied the company has raised its concerns with the
U.S. government.
The wholesale acquisition cost of the prostate cancer drug
Xtandi, marketed by Astellas Pharma Inc. of Japan and Medivation
Inc., is about $9,400 a month, compared with about $8,600 for rival
drug Zytiga from Johnson & Johnson. A Business News article
Thursday about a test that can identify patients unlikely to
benefit from either drug quoted Xtandi's price as more than
$10,000, using the average wholesale price, which is higher than
the wholesale acquisition cost.
(END) Dow Jones Newswires
July 09, 2016 02:47 ET (06:47 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Astellas Pharma (PK) (USOTC:ALPMY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Astellas Pharma (PK) (USOTC:ALPMY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Astellas Pharma Inc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Astellas Pharma, Inc. (PC)